GENB vs RXRX: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GENB and RXRX share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GENB and RXRX exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Generate Biomedicines, Inc. builds machine-learning models that design proteins from scratch and then runs the resulting molecules through conventional drug development. The lead program, GB-0895, is a long-acting anti-TSLP antibody for severe asthma engineered for roughly twice-yearly dosing, and it entered global Phase 3 studies (SOLAIRIA-1 and SOLAIRIA-2, about 1,600 patients) after a Phase 1 showed an approximately 89-day half-life. Behind it sit GB-4362, an antibody that mops up circulating MMAE payload to blunt the toxicity of antibody-drug conjugates, which carries FDA Fast Track designation, and GB-5267, a MUC16-directed CAR-T for ovarian cancer being run with Roswell Park. The platform also earns money directly: multi-program collaborations with Amgen and Novartis have paid roughly $110M to date and carry biobucks of up to about $2.9B in combined milestones.

Full GENB guide

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026) and comes mostly from partnerships rather than drug sales.

Full RXRX guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GENB drivers: GB-0895 and the six-month dosing pitch; Partner economics as validation and as cash.
• RXRX drivers: An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Binary clinical risk dominates everything else here: a Phase 3 miss on GB-0895, or a safety signal, would remove most of the value the market is currently assigning. For RXRX, the central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $117.5 million in Q1 2026 against only about $6.5 million of revenue, so the entire valuation rests on platform promise rather than proven output.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GENB if you believe its drivers more; RXRX if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GENB and RXRX guides.

GENB. No conventional valuation multiple works on a company whose only revenue is partner payments. Stripping out cash leaves an enterprise value near $1.8B for a platform, a Phase 3 antibody and two Phase 1 assets, which prices in a reasonable probability of GB-0895 reaching the market. Quarter-to-quarter revenue moves reflect collaboration milestones landing or not landing, so reading them as a growth trend tends to mislead.

RXRX. Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. Q1 2026 showed narrower losses driven by sizable cuts to R&D and overhead, which extended the stated runway into early 2028, but revenue came in well below analyst expectations. For a story like this, valuation is ultimately a bet on future platform output and partnership milestones rather than on current financial performance.

Headline figures (approximate, August 2026): GENB shows revenue (ttm) ~$26.5M, all collaboration revenue from Amgen and Novartis, net loss (ttm) ~$269M; ~$67.3M in Q2 2026 alone, cash and marketable securities ~$457M at June 30, 2026, guided to fund operations into H1 2028, market cap ~$2.3B on ~128M shares; RXRX shows revenue (q1 2026) ~$6.5 million (mostly partnership and milestone revenue, missed analyst estimates), net loss (q1 2026) ~$117.5 million (narrowed from the prior year on cost cuts), cash and investments ~$665 million (as of March 31, 2026), guided 2026 operating cash burn less than ~$390 million; stated runway into early 2028 without new financing.

GENB and RXRX are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GENB and RXRX exposure against your real portfolio. It is not an investment adviser.